Cell and Gene Therapy Catapult manufacturing center receives new investment

A £12 million award from the UK Government’s Industrial Strategy Challenge Fund will double the capacity of the Cell and Gene Therapy Catapult manufacturing center in Stevenage, UK.

Upvote 1 Comment

As part of a £197 million investment in the healthcare and life sciences sector, a £12 million award from the UK Government’s Industrial Strategy Challenge Fund will significantly increase the current size and capability of the Cell and Gene Therapy Catapult (CGT Catapult; London, UK) large-scale Good Manufacturing Practice (GMP) manufacturing center. The award, which builds on the current £55 million investment in the project, allows the center’s capacity to double, offering businesses developing cell therapy products further opportunities to accelerate trials and worldwide commercialization to bring these rapidly evolving medicines to patients.

The award, announced by Business Secretary Greg Clark and Health Secretary Jeremy Hunt, is part of the Government’s agenda to invest in best-in-class technology via Innovate UK and the Catapult Program, which speeds up the manufacture and market availability of innovative therapies while further building the exporting capability of the UK’s biopharmaceutical sector.

A further £30 million investment in new Advanced Therapies Treatment Centers, also announced today, will see the creation of three hospital-based sites designed to transform the UK’s ability to deliver cell and gene therapies to patients. Cell and gene therapies are a core component of a revolution in medicine across a broad array of disease areas and continued Government investment is helping us to rapidly evolve the UK as a global hub.

“Our mission is to facilitate the growth of a major UK industry, bringing transformative therapies to patients which present new options in challenging disease areas. Key to this is the availability of an advanced, robust supply and logistics infrastructure, which our novel manufacturing center delivers. Industry demand for these services is high and we are looking forward to welcoming our first collaborators to the center this year”, explained CGT Catapult CEO, Keith Thompson.

The Stevenage-based manufacturing center, scheduled to open in Autumn 2017, will provide the UK with the manufacturing facilities needed for large scale cell and gene therapy clinical studies and commercialization, in line with GMP standards. Its innovative business model will allow the development of new manufacturing processes in a collaborative environment.

The center features a series of large clean room modules which can be occupied by businesses conducting trials or commercial manufacture of these therapies at significant scale. The center is designed to help de-risk capital investment in product development by reducing the outlay required to bring trials to fruition and to collaborate on the new technologies needed in manufacture and supply from the factory to the bedside.

Learn more about the CGT Catapult from Keith Thompson in RegMedNet’s exclusive video interview, filmed at ISCT.

Go to the profile of The Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult

Growing the UK cell and gene therapy industry, delivering health and wealth.

The Cell Therapy Catapult is an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 100 employees focusing on cell and gene therapy technologies, we work with our partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world.


Go to the profile of James L. Sherley, M.D., Ph.D.

Given these exciting resource developments, we at Asymmetrex hope that Catapult stem cell therapy process engineers with visit http://asymmetrex.com/our-serv... and get us involved as essential partners in their future endeavors to accelerate development of new stem cell-based therapies that use natural tissue stem cells.  We have the best tools for manufacturing tissue stem cells specifically, instead of the more abundant non-stem committed cells that always accompany them.

James L. Sherley, M.D., Ph.D.

Founder and Director, Asymmetrex